Corwin J, Lindberg R D
Cancer. 1979 Mar;43(3):1007-13. doi: 10.1002/1097-0142(197903)43:3<1007::aid-cncr2820430333>3.0.co;2-4.
Solitary plasmacytoma of bone (SPB) and extramedullary plasmacytoma (EMPC) are unusual solitary tumors of plasma cell origin. The clinical differences between these tumors and multiple myeloma are the subject of continued study. This review examines the radiotherapy experience at M. D. Anderson Hospital. Between 1948 and 1977, 12 patients with SPB and 12 patients with EMPC were treated with radiotherapy. Radiotherapeutic doses were most often (22/24) greater than 4,000 rads, at 200 rads per day. In order to qualify as solitary plasmacytoma a disease-free interval of 3 years was required. In the group of SPB, 5 patients of 9 were alive with no evidence of disease (NED) at 3 years, 4 of 5 at 5 years, and none of 4 at 10 years. In the EMPC group, 8 patients of 11 were NED at 3 and 5 years, and 6 of 9 at 10 years. Six patients with SPB developed multiple myeloma compared with only two with EMPC. The results confirm the better prognosis of EMPC and support the theory that SPB and EMPC are two different entities.
骨孤立性浆细胞瘤（SPB）和髓外浆细胞瘤（EMPC）是罕见的起源于浆细胞的孤立性肿瘤。这些肿瘤与多发性骨髓瘤之间的临床差异仍是持续研究的主题。本综述探讨了MD安德森医院的放疗经验。1948年至1977年间，12例SPB患者和12例EMPC患者接受了放射治疗。放疗剂量大多（22/24）超过4000拉德，每日200拉德。为符合孤立性浆细胞瘤的诊断标准，要求无病生存期达3年。在SPB组中，9例患者中有5例在3年时无疾病证据（NED）存活，5例中有4例在5年时存活，4例中无一例在10年时存活。在EMPC组中，11例患者中有8例在3年和5年时NED，9例中有6例在10年时NED。6例SPB患者发展为多发性骨髓瘤，而EMPC患者仅有2例。结果证实EMPC预后较好，并支持SPB和EMPC是两种不同实体的理论。
